Kenneth Shain is an Oncology physician affiliated with University of South Florida. OpenAlex indexes 530 publications with 7,405 citations (h-index 42).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
12902 Usf Magnolia Dr
Tampa, FL 336129416
Telephone
813-745-7365Provider last certified this registry record 17 Nov 2025.
Industry payments
18 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GlaxoSmithKline, LLC.Program year20254 payments$23,324openpaymentsdata.cms.gov ↗
- Janssen Biotech, Inc.Program year202533 payments
- Janssen Scientific Affairs, LLCProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
57.5%Thalidomide Analog48%Revlimid48%Lenalidomide32%Pomalyst20%Part D≥50 patientsKinase inhibitor7.7%Imbruvica71%Brukinsa29%Part D<11 patients+ 1 more class in this area
Nervous system
21.9%Opioid Agonist12.6%Oxycodone Hcl84%Tramadol Hcl17%Part D<11 patientsGabapentinoids5.3%Gabapentin61%Pregabalin39%Part D<11 patients+ 2 more classes in this area
Dermatology
13.7%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor13.7%Acyclovir100%Part D≥34 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2019–2019 per NIH RePORTER. The latest:
- CRM1 INHIBITORS SENSITIZE MULTIPLE MYELOMA CELLS TO TOPOISOMERASE II AND PROTEASOME INHIBITORS
H. Lee Moffitt Cancer Ctr & Res Inst
FY2019$409,701R01CA194051
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Genomic Classification and Individualized Prognosis in Multiple Myeloma
Journal of Clinical Oncology
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Richard Lockey, MD
University of South Florida
Robert Hauser, MD
University of South Florida
Selim Benbadis, MD
University of South Florida
Pedram Hamrah, MD
University of South Florida
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”